Novo Nordisk increases its full-year guidance as US sales of Ozempic and Wegovy soar.
For the third time this year, Novo Nordisk increased its full-year revenue and operating profit forecast on Friday. This was due to the company’s strong sales of its diabetic treatment Ozempic and weight-loss drug Wegovy in the US. On the news, Novo’s stock surged almost 5% to a record high before caving in and closing … Read more